KUALA LUMPUR (Bernama): The Health Ministry and the Institute for Clinical Research (ICR) have started clinical trials to study the use and efficacy of Ivermectin for high-risk Covid-19 patients at 12 of the ministry's hospitals.
Health director-general Tan Sri Dr Noor Hisham Abdullah said Ivermectin is a Food and Drug Administration (FDA) approved anti-parasitic drug widely used for treating several neglected tropical diseases, including onchocerciasis, strongyloidiasis and helminthiases, however, the evidence is inconclusive to recommend routine use of Ivermectin for Covid-19 patients.
